Aprea Therapeutics Announces Pricing of Initial Public Offering
03 October 2019 - 1:03PM
Aprea Therapeutics, Inc., a biopharmaceutical company focused on
developing and commercializing novel cancer therapeutics that
reactivate mutant tumor suppressor protein, p53, today announced
the pricing of its initial public offering of 5,666,667 shares of
its common stock at a price to the public of $15.00 per share. The
shares are expected to begin trading on the Nasdaq Global Select
Market on October 3, 2019, under the ticker symbol “APRE.” The
gross proceeds of the offering, before deducting underwriting
discounts and commissions and other offering expenses, are expected
to be approximately $85 million. Aprea has granted the underwriters
a 30-day option to purchase up to an additional 850,000 shares of
common stock at the public offering price less underwriting
discounts and commissions. The offering is expected to close on
October 7, 2019, subject to the satisfaction of customary closing
conditions.
J.P. Morgan, Morgan Stanley and RBC Capital Markets are acting
as joint book-running managers for the offering. The offering is
being made only by means of a prospectus, copies of which may be
obtained, when available, from: J.P. Morgan Securities LLC, c/o
J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone, at (866) 803-9204; Morgan Stanley, 180 Varick Street,
2nd Floor, New York, NY 10014, Attention: Prospectus Department or
via email: prospectus@morganstanley.com; or RBC Capital Markets,
LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New
York, NY 10281, or by telephone, at (877) 822-4089.
A registration statement relating to these securities has been
filed with the U.S. Securities and Exchange Commission and has been
declared effective under the Securities Act of 1933, as amended.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described above, nor
shall there be any sale of such securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company
headquartered in Boston, Massachusetts with research facilities in
Stockholm, Sweden, focused on developing and commercializing novel
cancer therapeutics that reactivate mutant tumor suppressor
protein, p53. The Company’s lead product candidate is APR-246, a
small molecule in clinical development for hematologic
malignancies, including myelodysplastic syndromes (MDS) and acute
myeloid leukemia (AML).
Corporate Contacts:
Christian S. Schade
President and Chief Executive Officer
chris.schade@aprea.com
Gregory A. Korbel
Vice President of Business Development
greg.korbel@aprea.com
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024